Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
- Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis
September 11, 2014
- Drug Costs Made Up 21.9% of Japan Healthcare Spending in FY2011: MHLW
September 11, 2014
- MLHW to Issue Development Request for Vaccines that Require Fewer Doses
September 11, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- Jichi Medical University President Seen as Prime Candidate for Japan NIH Head
September 10, 2014
- Takeda Chairman Removed from Competitiveness Panel
September 9, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 25 – September 5
September 8, 2014
- Two Female Lawmakers Named New Senior Vice Health Ministers
September 8, 2014
- PAFSC’s Second Committee Backs Approval of Nobelpharma’s Anticancer Drug, MSD’s Hepatitis C Treatment
September 8, 2014
- PAFSC’s First Committee Supports Approval of Lixiana’s Additional Indications
September 5, 2014
- New Health Minister Plays it Safe, Promises to Follow Cabinet Decision on NHI Price Revision Frequency
September 5, 2014
- Industry on Alert as Reformist Shiozaki Tapped as New Health Minister
September 4, 2014
- PFSB Issues Notification on Submission of Package Inserts Under New Act
September 4, 2014
- LDP’s Niwa Says Treatment of Post-HPV Vaccine Adverse Reactions Top Priority
September 3, 2014
- MHLW to Consider Another Punishment or Action against Novartis Pharma: Minister
September 3, 2014
- Yasuhisa Shiozaki Tapped as New Health Minister
September 3, 2014
- MHLW Will Discuss Freezing NHI Prices of Essential Drugs if Industry Requests It: MHLW Official Nakai
September 3, 2014
- MOF Official Unami Urges Full-Scale NHI Price Revision upon Next Sales Tax Hike
September 2, 2014
- METI to Request 20% Increase in Budget for Promotion of Science and Technology: FY2015 Budget Request
September 2, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…